Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
Immunotherapy and Chemotherapy Shrink Peritoneal Mesothelioma Tumors: New Case Reports
Two new case reports appear to support the idea that immunotherapy and chemotherapy can work together to fight peritoneal mesothelioma. The case reports appears in the newest issue of the Journal of Immunotherapy. It details the cases of two patients with malignant peritoneal mesothelioma – a lethal cancer of the lining of the abdomen. Both patients relapsed on standard platinum-based chemotherapy. But adding an immune checkpoint inhibitor dramatically improved their results. In one case, a patient’s tumor nearly disappeared. Doctors at New York’s Memorial Sloan Kettering Cancer Center say the cases suggest that immunotherapy and chemotherapy might offer an alternative for patients who have run out of options. Alternative Treatments Needed for Peritoneal Mesothelioma About a fifth of patients who … Continue reading Immunotherapy and Chemotherapy Shrink Peritoneal Mesothelioma Tumors: New Case Reports
Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction
A new Dutch study offers some clues that might help doctors predict the effectiveness of Keytruda (pembrolizumab) in individual mesothelioma patients. Keytruda is the brand name for pembrolizumab. It is an immunotherapy drug called an immune checkpoint inhibitor. It helps unmask mesothelioma cells so that the immune system can find and fight them. But the effectiveness of Keytruda is not consistent. Some patients respond well while others do not respond at all. The new study looked at how different people metabolize the drug. Understanding this could help doctors determine the best dose for each mesothelioma patient. Pembrolizumab and its Link to Mesothelioma Survival Malignant pleural mesothelioma is a deadly form of lung cancer. Asbestos exposure is the main cause of … Continue reading Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction
Latest Keytruda Study Shows Limited Results for Most Mesothelioma Patients
Results of the latest Keytruda study show the drug works well for a select few mesothelioma patients, but not well at all for most others. Keytruda is the brand name for pembrolizumab. It is a type of immunotherapy drug. Early studies suggested that Keytuda might offer real hope for people with the aggressive cancer, malignant pleural mesothelioma. But the latest Keytruda study shows most patients do not have lasting results with this treatment. That is especially true for patients whose cells do not express high levels of the protein PD-1. How the Latest Keytruda Study Worked Keytruda is an immunotherapy drug. It works by activating the immune system. Mesothelioma cells can use a protein called PD-1 to protect themselves from … Continue reading Latest Keytruda Study Shows Limited Results for Most Mesothelioma Patients
Immunotherapy with Keytruda for Mesothelioma: A New Case Report
There’s more encouraging news about immunotherapy with Keytruda for people with pleural mesothelioma. The latest report comes from the University of Kansas School of Medicine. A doctor in the orthopaedic department at the school has malignant pleural mesothelioma. He and three colleagues recently published news of his “prompt and exceptionally favorable” response to firstline treatment with pembrolizumab. Pembrolizumab (Keytruda) is an immune checkpoint inhibitor. Several studies suggest that adding immunotherapy with Keytruda to other mesothelioma treatments may improve outcomes. But the new case report indicates that Keytruda could also be a good firstline option for some mesothelioma patients. How Immunotherapy with Keytruda Works Immunotherapy is a form of cancer treatment that uses the body’s immune system against the cancer. … Continue reading Immunotherapy with Keytruda for Mesothelioma: A New Case Report
First Patient Dosed in New Trial for Relapsed Mesothelioma
Doctors in the UK have started treatment on the first patient in the trial of a new drug combination for relapsed mesothelioma. The drug is called bemcentinib. It blocks a protein encoded by the AXL gene. People with mesothelioma tend to overexpress this protein. Studies show that this extra AXL protein might help cancer cells hide from the immune system. It might also help them spread to other parts of the body. In the new trial, patients with relapsed mesothelioma will get a combination of bemcentinib and Keytruda (pembrolizumab). Keytruda is an immunotherapy drug. Like bemcentinib, it helps make mesothelioma cells vulnerable to immune system attack. Animal studies and tests in lung cancer patients show that bemcentinib may help immune … Continue reading First Patient Dosed in New Trial for Relapsed Mesothelioma
FDA Approval of Keytruda will Help Some Mesothelioma Patients
The FDA approval of Keytruda this month may help some patients in their battle against asbestos cancer. Keytruda is the brand name for the immunotherapy drug pembrolizumab. The FDA first approved Keytruda as a first-line treatment for metastatic non-small cell lung cancer. That initial approval came in 2017. The new FDA approval of Keytruda is for treatment of specific kinds of malignant tumors. Eligible patients must have unresectable mesothelioma and no other treatment options. How Keytruda Fights Mesothelioma Keytruda is an immune checkpoint inhibitor. It blocks a protein called PD-L1. Mesothelioma cells use PD-L1 to avoid immune system attack. Drugs like Keytruda unmask these hiding cells and make them more vulnerable to treatment. But not all patients with mesothelioma will … Continue reading FDA Approval of Keytruda will Help Some Mesothelioma Patients
Amazing Keytruda Case Study Offers Hope for Advanced Mesothelioma
Italian doctors are reporting an “impressive clinical response” in a recently published Keytruda case study. The case is encouraging news for people with advanced malignant mesothelioma. The case involves a 45-year-old woman with metastatic pleural mesothelioma. Doctors found cancer in her chest, brain, and abdomen. Even after several kinds of chemotherapy, the patient continued to go down hill. Finally, when it looked like the woman would not live much longer, doctors tried Keytruda (pembrolizumab). The Keytruda case study documents the patient’s amazing turnaround. Case Looked Hopeless The 45-year old woman in the Keytruda case study first went to the doctor because of shortness of breath. Doctors found that she had pleural effusion. This is a build-up of lung fluid that … Continue reading Amazing Keytruda Case Study Offers Hope for Advanced Mesothelioma
Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results
There has been a setback for researchers focused on the promise of pembrolizumab for mesothelioma. New research suggests that pembrolizumab (Keytruda) may not be the miracle mesothelioma drug that some were hoping for. The Phase III trial results were presented at a the European Society of Medical Oncology conference now underway in Spain. They suggest that pembrolizumab for mesothelioma may be no better than chemotherapy for improving survival. Pembrolizumab for Mesothelioma: How it Works Malignant pleural mesothelioma is a rare but lethal cancer. It is usually associated with on-the-job asbestos exposure. There is no cure. The only drug approved for mesothelioma treatment is Alimta (pemetrexed). Cancer researchers around the world are working hard to find other mesothelioma treatments. Pembrolizumab for … Continue reading Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results
First-Line Keytruda Treatment May Support Longer Mesothelioma Survival
New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona. The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer. Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line … Continue reading First-Line Keytruda Treatment May Support Longer Mesothelioma Survival
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!